Winthrop Capital Management LLC Buys 1,615 Shares of AbbVie Inc. $ABBV

Winthrop Capital Management LLC raised its stake in AbbVie Inc. (NYSE:ABBV) by 61.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,247 shares of the company’s stock after purchasing an additional 1,615 shares during the period. Winthrop Capital Management LLC’s holdings in AbbVie were worth $788,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Midwest Trust Co purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $89,047,000. Acadian Asset Management LLC boosted its stake in AbbVie by 260.0% in the second quarter. Acadian Asset Management LLC now owns 513,887 shares of the company’s stock valued at $95,378,000 after acquiring an additional 371,131 shares in the last quarter. Global Wealth Management Investment Advisory Inc. grew its holdings in AbbVie by 16.2% in the second quarter. Global Wealth Management Investment Advisory Inc. now owns 42,216 shares of the company’s stock worth $7,836,000 after purchasing an additional 5,884 shares during the last quarter. CSM Advisors LLC purchased a new position in AbbVie in the second quarter worth $17,945,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of AbbVie by 35.2% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 116,667 shares of the company’s stock worth $21,656,000 after purchasing an additional 30,390 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

ABBV opened at $218.92 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The firm has a 50 day moving average of $223.24 and a two-hundred day moving average of $202.50. The firm has a market capitalization of $386.92 billion, a PE ratio of 104.25, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 524.24%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ABBV shares. Wells Fargo & Company raised their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Evercore ISI boosted their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Hsbc Global Res downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, Bank of America lifted their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $236.57.

Insider Activity

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.25% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.